HPV 16 E6 (18-26) Peptide
A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2. Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV. (NCI04) [ ]
Term info
HPV 16 E6 (18-26) Peptide
- HPV 16 E6 (18-26) Peptide
- HPV 16 E6:18-26
http://purl.obolibrary.org/obo/NCIT_C1397
HPV_16_E6_18-26_Peptide
673924
HPV 16 E6 (18-26) Peptide
Pharmacologic Substance, Amino Acid, Peptide, or Protein
C1512317
C38117
Term relations
- Human Papilloma Virus Vaccine
- Antineoplastic Vaccine
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Activation
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Antigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation